ArrowMark Colorado Holdings’s Syndax Pharmaceuticals SNDX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-497,801	Closed	-$5.82M	–	349
2017 Q3	$5.82M	Buy	497,801 +31,374	+7%	+$385K	0.07%	205
2017 Q2	$6.52M	Sell	466,427 -38,270	-8%	-$437K	0.08%	193
2017 Q1	$6.92M	Buy	504,697 +238,533	+90%	+$2.48M	0.09%	165
2016 Q4	$1.91M	Sell	266,164 -201,297	-43%	-$2.21M	0.03%	219
2016 Q3	$7.09M	Buy	467,461 +294,828	+171%	+$3.88M	0.13%	148
2016 Q2	$1.7M	Buy	172,633 +22,702	+15%	+$311K	0.03%	205
2016 Q1	$2M	Buy	+149,931	New	+$1.88M	0.04%	183

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ArrowMark Colorado Holdings's SNDX Position: Q4 2017 in Review

ArrowMark Colorado Holdings sold out of Syndax Pharmaceuticals (SNDX) in Q4 2017, closing a stake of 497,801 shares — an estimated $5.82M sold.

ArrowMark Colorado Holdings first reported a position in SNDX in Q1 2016 and held it in 7 quarters. The position peaked at $7.09M in Q3 2016. 80 funds tracked by Wall St. Rank hold SNDX as of Q4 2017.

ArrowMark Colorado Holdings reported no remaining Syndax Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
ArrowMark Colorado Holdings sold 497,801 Syndax Pharmaceuticals shares in Q4 2017, an estimated $5.82M.
ArrowMark Colorado Holdings first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 7 quarters.
ArrowMark Colorado Holdings's Syndax Pharmaceuticals position peaked at $7.09M in Q3 2016.
80 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2017.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.